Compare Adaptive Biotechnologies Corp (ADPT) vs Direxion Daily Semiconductor Bull 3X Shares (SOXL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Direxion Daily Semiconductor Bull 3X Shares — how do they compare? Adaptive Biotechnologies Corp trades at $19.87 (market cap $3.33B), while Direxion Daily Semiconductor Bull 3X Shares trades at $174.57. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, Direxion Daily Semiconductor Bull 3X Shares nearer its low. Which is the better fit depends on your goals.
| ADPT | SOXL | |
|---|---|---|
Market Cap | $3.33B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $22.37 | $300.77 |
52-Week Low | $10.24 | $23.99 |
Enterprise Value | $3.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
SOXL, a 3x leveraged semiconductor ETF, trades at $194.65, up 7.26% in 24 hours but remains in a bearish technical trend. Recent volatility includes a 16% single-day drop on July 1, 2026 (24/7 Wall Street), highlighting risks of leveraged decay. News sentiment is mixed, with JPMorgan advocating buying the chip dip while Morgan Stanley notes investor rotation away from semiconductors. Key support lies at $189, with resistance at $200.
Outlook is highly speculative due to leverage amplifying sector swings. Opportunities exist for tactical traders betting on semiconductor rebounds, but risks of rapid decay in choppy markets are severe. Long-term holders face structural erosion from volatility, making SOXL unsuitable for buy-and-hold strategies amid elevated sector uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Direxion Daily Semiconductor Bull 3X Shares
SOXL is a leveraged ETF that seeks daily investment results corresponding to 300% of the daily performance of the ICE Semiconductor Index. It is designed as a tactical tool for experienced traders to take a bullish (long) position on the semiconductor sector. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on SOXL →
